www.fdanews.com/articles/82272-johnson-johnson-neutral-target-price-reduced
JOHNSON & JOHNSON 'NEUTRAL,' TARGET PRICE REDUCED
November 8, 2005
Analyst Glenn Novarro of Banc of America Securities maintains his "neutral"
rating on Johnson & Johnson. The target price has been reduced from $72
to $65.
Newratings